What is Arocell?
Saving lives with diagnostics.
– We provide knowledge to decision.
– AroCell Group consist of AroCell AB and IDL Biotech.
See AroCell’s presentation at Stockholm Corporate Finance Life Science Capital Markets Days
On March 9, AroCell, Anders Hultman CEO, presented the latest developments and the future of the company at the Stockholm Corporate Finance Life Science Capital Markets Days at the IVA conference center in Stockholm. Stockholm Corporate Finance arranged the capital...
Kampen mot cancer samarbete – Så kan nya blodtestet hjälpa läkare avgöra om terapin fungera
CEO, Anders Hultman, Commenting on FDA delay due to Covid-19
This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA...
UBC® Rapid | Bladder Cancer detection
A powerful Doctors-office test (Point-of-Care), for aid in the diagnosis and monitoring of bladder cancer. Read more about UBC® Rapid
TUBEX® TF | Rapid Typhoid Detection
A rapid and sensitive in vitro diagnostic test for detection of acute typhoid fever, a disease caused by Salmonella typhi. Read more about TUBEX® TF
TK 210 ELISA | Cell Proliferation Biomarker
The AroCell TK 210 ELISA kit used for therapy response in subjects with many forms of cancer including several solid tumors. Read more about TK 210 ELISA
Tumor markers licensed to strategic partners
Arocell is constantly building partnerships for establishing projects and developing new products to expand its portfolio. Read More about tumor markers
Press Releases
About us
We provide knowledge to decision.
IDL Diagnosticsis a Swedish diagnostics company with the vision to improve the monitoring of oncological and bacterial diseases. We have a broad product portfolio of IVD tests that deliver high-value clinical information for the detection of diseases.
Investors
We are listed on NASDAQ First North Growth Market.
We want to be the obvious choice within our segment in the markets where we are established. The market for our products is large and we are a smaller player with significant growth potential so far. IDL Diagnostics is unique for a company of this size.
